Sign in
Taking people in United StatesPhase 2

Relugolix and enzalutamide with radiation for very high risk prostate cancer

Tests relugolix and enzalutamide with radiation in men with very high risk prostate cancer.

Key facts

Who runs it
Sean Sachdev
Where
Chicago, United StatesSee the site
Trial code
Registry title
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
6 Sept 2024
Expected to end
19 Nov 2032
Type of study
Interventional
Treatments tested
  • Biopsy
  • Biospecimen Collection
  • Computed Tomography
  • Enzalutamide
  • Fluorine F 18 Piflufolastat
  • Image Guided Radiation Therapy
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
  • Questionnaire Administration
  • Relugolix
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with very high risk prostate cancer that has not spread to distant parts of the body. They would get relugolix and enzalutamide together with radiation therapy.

Age
18 years or older
Sex
Men only
Disease stage
Prostate adenocarcinoma confirmed by biopsy, in the very-high-risk group (NCCN very-high-risk). Cancer in pelvic lymph nodes below the common iliac bifurcation is allowed if the very-high-risk criteria are met.
Earlier treatment
Earlier androgen deprivation therapy can be allowed if it lasted less than 60 days in total. Testosterone must be 50 ng/dL or more before joining. 5-alpha reductase inhibitors must be stopped before the trial treatment starts.
Biomarker or test result
Testosterone above 50 ng/dL within 90 days before registration.

Main reasons for not taking part

  • Clear signs of cancer that has spread (metastatic disease) on exams or scans
  • Another invasive cancer, unless free of disease for at least 2 years
  • Earlier radiation that would overlap the new radiation fields
  • Inflammatory bowel disease, serious heart failure or unstable angina in the last 4 months, or seizure disorder
  • Cannot take oral medicine, or has a bowel condition that stops the drugs from being absorbed

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients must have histologically confirmed prostate adenocarcinoma consistent with NCCN very-high-risk (VHR) prostate cancer defined with at least one of the following:; cT3b-cT4 (American Joint Committee on Cancer [AJCC] 9.0); > 4 cores with grade group 4 or 5 prostate cancer; Primary gleason pattern 5; 2 or 3 NCCN high-risk features
  • Patients with involved pelvic lymph nodes below the common iliac bifurcation will be allowed as long as the criteria for VHR (very-high risk) are met
  • Patients must be age ≥ 18 years
  • Patients must have testosterone > 50 ng/dL within 90 days prior to registration; Note: Prior androgen deprivation (gonadotrophin releasing hormone [GnRH] analog and/or non-steroidal antiandrogen) therapy is allowed provided that it is less than 60 days of prior total duration and that serum testosterone concentration must be ≥ 50 ng/dL prior to enrollment; 5-alpha reductase inhibitors will not impact eligibility, but must be discontinued prior to starting protocol treatment
  • Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Leukocytes (white blood cells [WBC]) ≥ 2,500/mcL
  • Absolute neutrophil count (ANC) ≥ 1,500/mcL
  • Hemoglobin (Hgb) ≥ 8 g/dL
  • Platelets (PLT) ≥ 80,000/mcL
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) ≤ 3 x institutional upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional ULN
  • Creatinine ≤ institutional ULN
  • Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m\^2; Estimated GFR (eGFR) is estimated GFR calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation
  • For patients with a known history of human immunodeficiency virus (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 3 months prior to registration with a CD4 count of ≥ 200 cells/μL. Note also that HIV testing is not required for eligibility for this protocol as it is self-reported
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be better than class III
  • Patients must not have contraindications to magnetic resonance (MR) imaging and be able to lie flat and still for approximately 30-40 minutes and be able to tolerate PET/CT imaging and radiation therapy treatment planning and delivery
  • Patients with female partners of reproductive potential must agree to use effective contraception during treatment with and for 3 months after the last dose. Male patients must use a condom during sex with a pregnant woman
  • Patients must have the ability to understand and the willingness to sign a written informed consent document and comply with the study requirements

Who cannot take part

  • Prior radiotherapy that would result in overlap of radiation therapy fields
  • Patients who have a history of any of the following:; History of documented inflammatory bowel disease; Symptomatic congestive heart failure (New York Heart Association Functional Classification III/IV) within 4 months prior to registration; Unstable angina pectoris requiring hospitalization within the last 4 months prior to registration; History of seizure disorder or condition that may yield a high risk of seizure (e.g., prior cortical stroke or significant brain trauma); Psychiatric illness/social situations that would limit compliance with study requirements; History of repeated falls and fractures over the past 12 months that in the opinion of the treating investigator would put the patient at risk for poor bone outcomes from androgen receptor targeted therapy; Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints; Patients with the inability to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of enzalutamide and relugolix
  • Patients with definitive clinical or radiologic evidence of metastatic disease
  • Patients with prior invasive malignancy (except non-melanomatous skin cancer carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma) unless disease free for a minimum of 2 years

Where in United States

  • Northwestern UniversityChicago, United StatesContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy. It prevents the release of testosterone, a hormone required to sustain prostate growth. Reducing testosterone levels may inhibit the proliferation of prostate tumor cells that need testosterone to grow. Enzalutamide is an androgen receptor signaling inhibitor. It inhibits the activity of prostate tumor cell receptors, which may reduce proliferation of prostate tumor cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Adding relugolix and enzalutamide to radiation therapy may be more effective at treating patients with very high risk prostate cancer than giving any of these treatments alone.

The group in the trial

  • Treatment (relugolix, enzalutamide, IGRT)Treatment being tested

    Patients receive relugolix PO QD and enzalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. After 4 months of treatment with relugolix and enzalutamide, patients begin IGRT per standard of care. Patients also undergo fluorine F 18 piflufolastat PET/MRI and CT on the trial, undergo collection of blood samples throughout the trial, and undergo biopsy during follow up.

    Treatment: Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, and Relugolix

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimizing Treatment and Advanced Multi-Imaging Response Evaluation for Very-High-Risk Prostate Cancer (OPTIMAL) - a Phase II Single Arm Study
Plain-language title
Relugolix and enzalutamide with radiation for very high risk prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 October 2026